If your interest is the sexual health application, PT-141 is an FDA-approved option addressing that pathway with established safety data
Most patients inject once weekly and notice strongest appetite suppression within 48-72 hours
FDA may issue no objection (the company may market, though this is not approval) or object (e.g., safety concerns or incomplete data)
GLD-1 (a KH-motif RBP) and NOS-3 (Nanos protein family member) form a translational repression pathway (Hansen et al., 2004), while the cytoplasmic poly(A) polymerase formed by the complex of GLD-2 [the poly(A) polymerase enzyme] and GLD-3 (a homolog of Bicaudal-C RBP) constitutes a translational activation pathway (Eckmann et al., 2004)
This doesnt mean protein is unimportant
in some trials, the incidence was more than 10% higher compared to placebo [14]